{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:56:27Z","timestamp":1792176987325,"version":"4.4.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"1_suppl","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To provide an overview on commercially available point-of-care tests (POCT) for rapid assessment of direct oral anticoagulant (DOAC) activity, their diagnostic accuracy in identifying blood samples containing clinically relevant DOAC concentrations, and guidance on selecting the appropriate POCT system\/assay for decision-making in emergencies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Systematic review with PubMed and Cochrane library search for published studies until September 6, 2024. Papers were included if in English, original research using blood samples from DOAC patients and POCT was implemented. Two reviewers assessed studies for eligibility and quality. Data from studies were aggregated and diagnostic accuracy at DOAC plasma thresholds of 30\/50\/100 ng\/ml was recalculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>16 studies involving four commercially available POCT systems\/assays were identified. Eleven studies evaluated blood-based POCT and five used urine for indirect estimation of DOAC plasma levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>DOAC Dipsticks do not require knowledge about the taken DOAC, but measure urine and, due to low specificity, require blood testing in case of positive results. Hemochron Signature Elite (HSE) and CoaguChek use global coagulation assays and provide high sensitivity for edoxaban and rivaroxaban, HSE additionally for dabigatran. Due to insufficient correlation, both POCT are not recommended for apixaban, CoaguChek also not for dabigatran. The thromboelastometric ClotPro performs well for all DOAC, does not require knowledge about the DOAC, but was taken off the market recently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Studies have shown feasibility of POCT in identifying blood samples containing clinically relevant DOAC plasma concentrations. Each POCT device has its own unique limitations. Knowledge about the POCT assays, time since last intake and type of DOAC enhances confidence in making appropriate therapeutic decisions. We propose an algorithm that could help guiding physicians in selecting an appropriate POCT system\/assay in DOAC-related emergencies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23969873241310359","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:00:24Z","timestamp":1747897224000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Rapid assessment of direct oral anticoagulants in acute stroke\u2014An educational systematic review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0108-9161","authenticated-orcid":false,"given":"Joshua","family":"Mbroh","sequence":"first","affiliation":[{"name":"Department of Neurology & Stroke, University of T\u00fcbingen, T\u00fcbingen, Germany 1"},{"name":"Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, T\u00fcbingen, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingvild","family":"Birschmann","sequence":"additional","affiliation":[{"name":"Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center, Ruhr University, Bad Oeynhausen, Germany 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ebner","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum der Charit\u00e9, Department of Cardiology, Angiology and Intensive Care Medicine, Berlin, Germany 4"},{"name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin, Berlin, Germany 5"},{"name":"German Center for Cardiovascular Research (DZHK), Partner site Berlin, Berlin, Germany 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna A.","family":"Kremer Hovinga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edelgard","family":"Lindhoff-Last","sequence":"additional","affiliation":[{"name":"Vascular Center, Coagulation Center and Coagulation Research Center, CardioAngiology Center (CCB) Bethanienhospital, Frankfurt, Germany 8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Purrucker","sequence":"additional","affiliation":[{"name":"Department of Neurology, Heidelberg University Hospital, Heidelberg, Germany 9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon T.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, Intensive Care Medicine, Emergency Medicine and Pain Therapy, University Hospital, Carl-von-Ossietzky University Oldenburg, Klinikum Oldenburg A\u00f6R, Oldenburg, Germany 10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"T\u00fcnnerhoff","sequence":"additional","affiliation":[{"name":"Department of Neurology & Stroke, University of T\u00fcbingen, T\u00fcbingen, Germany 1"},{"name":"Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, T\u00fcbingen, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology & Stroke, University of T\u00fcbingen, T\u00fcbingen, Germany 1"},{"name":"Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, T\u00fcbingen, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0286-8781","authenticated-orcid":false,"given":"Sven","family":"Poli","sequence":"additional","affiliation":[{"name":"Department of Neurology & Stroke, University of T\u00fcbingen, T\u00fcbingen, Germany 1"},{"name":"Hertie Institute for Clinical Brain Research, University of T\u00fcbingen, T\u00fcbingen, Germany 2"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"2026012113080922300_bibr1-23969873241310359","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026012113080922300_bibr2-23969873241310359","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe","journal-title":"Eur Heart J"},{"key":"2026012113080922300_bibr3-23969873241310359","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New England J Med"},{"key":"2026012113080922300_bibr4-23969873241310359","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2026012113080922300_bibr5-23969873241310359","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2026012113080922300_bibr6-23969873241310359","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New Eng J Med"},{"key":"2026012113080922300_bibr7-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1161\/svin.121.000146","article-title":"Trends in the use of oral anticoagulants and associated expenditures among medicaid programs","volume":"1","author":"Kim","year":"2021","journal-title":"Stroke: Vasc Int Neurol"},{"key":"2026012113080922300_bibr8-23969873241310359","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/a-1549-6556","article-title":"Pharmacokinetics of direct oral anticoagulants in emergency situations: results of the prospective observational RADOA-registry","volume":"122","author":"Lindhoff-Last","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr9-23969873241310359","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5853\/jos.2017.00395","article-title":"Intravenous thrombolysis in patients with stroke taking rivaroxaban using drug specific plasma levels: experience with a standard operation procedure in clinical practice","volume":"19","author":"Seiffge","year":"2017","journal-title":"J Stroke"},{"key":"2026012113080922300_bibr10-23969873241310359","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012113080922300_bibr11-23969873241310359","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012113080922300_bibr12-23969873241310359","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"2026012113080922300_bibr13-23969873241310359","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41467-024-48278-1","article-title":"Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding","volume":"15","author":"Jankowski","year":"2024","journal-title":"Nat Commun"},{"key":"2026012113080922300_bibr14-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27058","article-title":"Before, during, and after: An Argument for Safety and Improved Outcome of Thrombolysis in Acute Ischemic Stroke with Direct Oral Anticoagulant Treatment","volume":"20240911","author":"Monjazeb","year":"2024","journal-title":"Ann Neurol"},{"key":"2026012113080922300_bibr15-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619872556","article-title":"Evaluation of the DOAC-stop procedure by LC-MS\/MS assays for determining the residual activity of dabigatran, rivaroxaban, and apixaban","volume":"25","author":"Slavik","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012113080922300_bibr16-23969873241310359","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.118.009807","article-title":"Limitations of specific coagulation tests for direct oral anticoagulants: a critical analysis","volume":"7","author":"Ebner","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026012113080922300_bibr17-23969873241310359","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11239-019-01981-z","article-title":"Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds","volume":"49","author":"Hartig","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113080922300_bibr18-23969873241310359","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1213\/ANE.0000000000005114","article-title":"Heparin anti-xa activity, a readily available unique test to quantify apixaban, rivaroxaban, fondaparinux, and danaparoid levels","volume":"132","author":"Boissier","year":"2021","journal-title":"Anesth Analg"},{"key":"2026012113080922300_bibr19-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12870","article-title":"Reduction of the turn-around time for the measurement of rivaroxaban and apixaban: assessment of the performance of a rapid centrifugation method","volume":"40","author":"Dincq","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"2026012113080922300_bibr20-23969873241310359","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ana.22355","article-title":"Point-of-care laboratory halves door-to-therapy-decision time in acute stroke","volume":"69","author":"Walter","year":"2011","journal-title":"Ann Neurol"},{"key":"2026012113080922300_bibr21-23969873241310359","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ana.21965","article-title":"Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage","volume":"67","author":"Rizos","year":"2010","journal-title":"Ann Neurol"},{"key":"2026012113080922300_bibr22-23969873241310359","doi-asserted-by":"publisher","first-page":"345138","DOI":"10.1155\/2015\/345138","article-title":"Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations","volume":"2015","author":"Douxfils","year":"2015","journal-title":"Biomed Res Int"},{"key":"2026012113080922300_bibr23-23969873241310359","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11239-014-1082-5","article-title":"Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests","volume":"38","author":"Lippi","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113080922300_bibr24-23969873241310359","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1161\/strokeaha.117.017981","article-title":"Emergency coagulation assessment during treatment with direct oral anticoagulants: limitations and solutions","volume":"48","author":"Ebner","year":"2017","journal-title":"Stroke"},{"key":"2026012113080922300_bibr25-23969873241310359","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2396987319863606","article-title":"Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018","author":"Ahmed","year":"2019"},{"key":"2026012113080922300_bibr26-23969873241310359","doi-asserted-by":"publisher","first-page":"0717","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"2024","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026012113080922300_bibr27-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13582","article-title":"Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants","volume":"25","author":"Touze","year":"2018","journal-title":"Eur J Neurol"},{"key":"2026012113080922300_bibr28-23969873241310359","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/europace\/euab217","article-title":"2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: comment","volume":"23","author":"Mbroh","year":"2021","journal-title":"Europace"},{"key":"2026012113080922300_bibr29-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2026012113080922300_bibr30-23969873241310359","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","journal-title":"J Clin Epidemiol"},{"key":"2026012113080922300_bibr31-23969873241310359","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"2026012113080922300_bibr32-23969873241310359","unstructured":"Lowry R. \u00a0Vassarstats: Website for Statistical Computation, http:\/\/vassarstats.net\/clin1.html (2013, accessed September 5 2024)."},{"key":"2026012113080922300_bibr33-23969873241310359","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4081\/btvb.2022.37","article-title":"Evaluation of Coaguchek\u00aePro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study","volume":"1","author":"Legnani","year":"2022","journal-title":"Bleed Thromb Vasc Biol"},{"key":"2026012113080922300_bibr34-23969873241310359","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1055\/a-1753-2748","article-title":"DOAC dipstick testing can reliably exclude the presence of clinically relevant DOAC concentrations in circulation","volume":"122","author":"Margetic","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr35-23969873241310359","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1055\/s-0042-1750327","article-title":"Performance of a qualitative point-of-care strip test to detect DOAC exposure at the emergency department: a cohort-type cross-sectional diagnostic accuracy study","volume":"122","author":"Merrelaar","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr36-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1177\/10760296221084307","article-title":"Evaluation of DOAC dipstick test for detecting direct oral anticoagulants in urine compared with a clinically relevant plasma threshold concentration","volume":"28","author":"Ord","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012113080922300_bibr37-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231179684","article-title":"Comparison of the DOAC dipstick test on urine samples with chromogenic substrate methods on plasma samples in outpatients treated with direct oral anticoagulants","volume":"29","author":"Papageorgiou","year":"2023","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012113080922300_bibr38-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.122.041555","article-title":"Assessment of direct oral anticoagulant status using the doasense dipstick in thrombolysis eligible patients with stroke: proof-of-concept Study","volume":"54","author":"Tan","year":"2023","journal-title":"Stroke"},{"key":"2026012113080922300_bibr39-23969873241310359","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/anae.15254","article-title":"A prospective observational study of the rapid detection of clinically-relevant plasma direct oral anticoagulant levels following acute traumatic injury","volume":"76","author":"Oberladstatter","year":"2021","journal-title":"Anaesthesia"},{"key":"2026012113080922300_bibr40-23969873241310359","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-017-1619-z","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants","volume":"21","author":"Ebner","year":"2017","journal-title":"Crit Care"},{"key":"2026012113080922300_bibr41-23969873241310359","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1161\/STROKEAHA.115.010148","article-title":"Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants","volume":"46","author":"Ebner","year":"2015","journal-title":"Stroke"},{"key":"2026012113080922300_bibr42-23969873241310359","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s11239-020-02143-2","article-title":"Point-of-care testing of coagulation in patients treated with edoxaban","volume":"50","author":"Hartig","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2026012113080922300_bibr43-23969873241310359","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42466-021-00105-4","article-title":"Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban","volume":"3","author":"Hartig","year":"2021","journal-title":"Neurol Res Pract"},{"key":"2026012113080922300_bibr44-23969873241310359","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620972473","article-title":"Effect of dabigatran on clotting time in the clotpro ecarin clotting assay: a prospective, single-arm, open-label study","volume":"26","author":"Fong","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"2026012113080922300_bibr45-23969873241310359","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12959-021-00267-w","article-title":"Viscoelastometry for detecting oral anticoagulants","volume":"19","author":"Groene","year":"2021","journal-title":"Thromb J"},{"key":"2026012113080922300_bibr46-23969873241310359","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1160\/TH13-10-0871","article-title":"Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"111","author":"Francart","year":"2014","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr47-23969873241310359","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/jth.12308","article-title":"Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels","volume":"11","author":"Hawes","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026012113080922300_bibr48-23969873241310359","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/FTD.0000000000000064","article-title":"Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant","volume":"36","author":"Mani","year":"2014","journal-title":"Ther Drug Monit"},{"key":"2026012113080922300_bibr49-23969873241310359","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in atients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2026012113080922300_bibr50-23969873241310359","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1055\/s-0038-1668098","article-title":"Detecting anti-IIa and anti-Xa direct oral anticoagulant (DOAC) agents in urine using a DOAC dipstick","volume":"45","author":"Harenberg","year":"2019","journal-title":"Sem Thromb Hemos"},{"key":"2026012113080922300_bibr51-23969873241310359","first-page":"157","volume-title":"Australasian Anaesthesia 2021","author":"Drummond","year":"2021"},{"key":"2026012113080922300_bibr52-23969873241310359","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"2026012113080922300_bibr53-23969873241310359","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1055\/a-2261-1811","article-title":"Algorithm for rapid exclusion of clinically relevant plasma levels of direct oral anticoagulants in patients using the DOAC dipstick: an expert consensus paper","volume":"124","author":"Harenberg","year":"2024","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr54-23969873241310359","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/rth2.12206","article-title":"Fully automated thromboelastograph TEG 6s to measure anticoagulant effects of direct oral anticoagulants in healthy male volunteers","volume":"3","author":"Artang","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"2026012113080922300_bibr55-23969873241310359","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/TA.0000000000002357","article-title":"Rapid point-of-care detection and classification of direct-acting oral anticoagulants with the TEG 6s: implications for trauma and acute care surgery","volume":"87","author":"Dias","year":"2019","journal-title":"J Trauma Acute Care Surg"},{"key":"2026012113080922300_bibr56-23969873241310359","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1515\/cclm-2013-0936","article-title":"Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests","volume":"52","author":"Eller","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2026012113080922300_bibr57-23969873241310359","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ijlh.12744","article-title":"Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)","volume":"40","author":"Seyve","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"2026012113080922300_bibr58-23969873241310359","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.thromres.2020.04.019","article-title":"Real-time detection and differentiation of direct oral anticoagulants (rivaroxaban and dabigatran) using modified thromboelastometric reagents","volume":"190","author":"Schafer","year":"2020","journal-title":"Thromb Res"},{"key":"2026012113080922300_bibr59-23969873241310359","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1055\/s-0040-1721775","article-title":"Specific point-of-care testing of coagulation in patients treated with dabigatran","volume":"121","author":"Hartig","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026012113080922300_bibr60-23969873241310359","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/ijlh.13591","article-title":"Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa","volume":"43","author":"Bourdin","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2026012113080922300_bibr61-23969873241310359","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/ejcts\/ezw368","article-title":"Direct oral anticoagulants and heparins: laboratory values and pitfalls in \u2018bridging therapy\u2019","volume":"51","author":"Eller","year":"2017","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["European Stroke Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23969873241310359","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23969873241310359","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/24\/64645682\/23969873241310359.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/esj\/article-pdf\/10\/1_suppl\/24\/64645682\/23969873241310359.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:38Z","timestamp":1769018918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/esj\/article\/10\/1_suppl\/24\/8268622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":61,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1177\/23969873241310359","relation":{},"ISSN":["2396-9873","2396-9881"],"issn-type":[{"value":"2396-9873","type":"print"},{"value":"2396-9881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4,1]]},"published":{"date-parts":[[2025,4,1]]}}}